Search results
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation - Regeneron...
Benzinga· 7 days agoEylea US sales fell 16% to $1.2 billion, primarily due to changing market dynamics, resulting in...
iGlarLixi Safe and Effective in Inadequately Controlled T2D
Medscape· 7 days agoA once-daily injectable therapy of a fixed-ratio combination of insulin glargine and lixisenatide...
Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of...
Lodi News-Sentinel· 18 hours agoInnovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology ...
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC)as...
The Yuma Sun· 3 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology ...
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 days agoKymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript May 3, 2024 Kymera...
Cracking The Code: Understanding Analyst Reviews For BioNTech - BioNTech (NASDAQ:BNTX)
Benzinga· 2 days agoExamining the current and prior targets offers insights into analysts' evolving expectations. For valuable insights into BioNTech's market performance, consider these analyst ...
Leukemia Therapeutics Market Expected to Grow at USD 13491.42 Million by 2030: SNS Insider
Digital Journal· 6 days agoThe global leukemia therapeutics market has witnessed significant growth in recent years, driven by...
IPC Develops Consensus on Generalized Pustular Psoriasis
Medscape· 2 days agoThe IPC's definition and diagnostic criteria for GPP minimized the complexity of clinical...
Don't Overlook Cardiovascular Risk in Type 1 Diabetes
Medscape· 2 days agoCardiovascular disease management is an often overlooked but critical aspect of care for people with...
Regeneron Reverses On Better-Than-Feared Eylea Sales
Investor's Business Daily· 7 days agoHigh-dose Eylea came in at $200 million, beating expectations for $189 million, Leerink Partners analyst David Risinger said in a report. The high dose...